People with type 2 diabetes who are treated with GLP-1 agonists have a decreased risk of developing dementia, according to a new study from Karolinska Institutet in Sweden published in the journal eClinicalMedicine.
GLP-1 agonists linked to reduced dementia risk in type 2 diabetes patients
- Post author:
- Post published:June 20, 2024
- Post category:uncategorized